Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antiparkinsonian

or Empathogen

or [[:Category:Antiemetics|Antiemetic]]

Use the filters below to narrow your results.

4-FA (1) · 5-APB (1) · 5-MAPB (1) · 6-APB (1) · 6-APDB (1) · Amantadine (1) · Apomorphine (1) · Benztropine (1) · Biperiden (1) · Bromocriptine (1) · Butylone (1) · Cabergoline (1) · Carbidopa/levodopa (1) · Diphenhydramine (hydrochloride; citrate) (1) · Entacapone (1) · Ephylone (1) · Ethylone (1) · Levodopa (1) · MDA (1) · MDAI (1) · MDEA (1) · MDMA (1) · Meclizine (1) · Mephedrone (1) · Methylone (1) · Metoclopramide (1) · Ondansetron (1) · Opicapone (1) · PMA (1) · PMMA (1) · Promethazine (hydrochloride) (1) · Rasagiline (1) · Rotigotine (1) · Safinamide (1) · Selegiline (1) · Tolcapone (1) · Trihexyphenidyl (1)

None (3) · Central and peripheral COMT inhibitor (1) · D1/D2/D3 receptor agonist (1) · D2 agonist; D1 partial agonist (1) · D2 receptor agonist (1) · Dopamine precursor (1) · Dopamine precursor + DOPA decarboxylase inhibitor (1) · Irreversible selective MAO-B inhibitor (2) · MAO inhibitor; monoamine releasing agent (1) · MAO inhibitor; serotonin releasing agent (1) · MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) · Monoamine releasing agent (3) · Monoamine releasing agent; 5-HT2A agonist (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Muscarinic receptor antagonist (1) · Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) · NMDA antagonist; dopamine releasing agent (1) · Non-selective dopamine receptor agonist (1) · Once-daily COMT inhibitor (1) · Peripheral COMT inhibitor (1) · Selective M1 muscarinic antagonist (1) · Serotonin releasing agent (2) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-00000013-QINU`"' Anticholinergic burden (dry mouth, blurred vision, urinary retention, cognitive effects) is the principal adverse-event concern and the basis for Beers-list cautions in elderly patients'"`UNIQ--ref-00000014-QINU`"'. (1) · '"`UNIQ--vote-0000001D-QINU`"' Major Beers-list concern in elderly patients for cognitive and fall risks. CYP2D6 substrate. At massive overdose, also produces sodium channel blockade with cardiac toxicity'"`UNIQ--ref-0000001E-QINU`"'. '"`UNIQ--effect-0000001F-QINU`"' (1)

None (32) · 10 mg PO/IV/IM QID, '''not to exceed 12 weeks''' (tardive dyskinesia risk); intranasal Gimoti 15 mg BID (1) · 4-8 mg PO or IV every 8 hours as needed; 16 mg single dose preoperatively for PONV prevention (1) · Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated''' (1) · Allergy: 25-50 mg PO every 4-6 hours. Insomnia: 25-50 mg PO at bedtime. IV (acute dystonia, severe allergic reaction): 25-50 mg slow IV push (1) · Motion sickness: 25-50 mg PO 1 hour before travel, repeat every 24 hours as needed. Vertigo: 25-100 mg/day divided (1)

None (32) · 4 mg, 8 mg, 24 mg tablets; 4 mg, 8 mg orally disintegrating tablets; 4 mg/5 mL oral solution; IV (2 mg/mL) (1) · 5, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL IV; 15 mg/spray intranasal (1) · Tablets 12.5, 25 mg; chewable tablets 25 mg (1) · Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL (1) · Tablets 25, 50 mg; capsules; liquid; chewable; topical cream/gel; injection 50 mg/mL (1)

None (32) · 100 mg/day (adult) (1) · 100 mg/day (vertigo) (1) · 300 mg/day (oral) (1) · 40 mg/d (1) · Single doses ≤16 mg (FDA 2012 advisory withdrew the 32 mg single IV dose for QT-prolongation risk); 24-32 mg/d divided (1)

None (32) · IM (4) · intranasal (1) · IV (3) · IV (with caution) (1) · Oral (5) · rectal (1) · topical (1)

None (32) · 15-30 minutes (oral); 1-2 minutes (IV) (1) · 20 minutes (oral); 5 minutes (IV) (1) · 30 minutes PO; minutes IV (1) · IV/IM 1-3 minutes; PO 30-60 minutes (1) · ~1 hour (1)

None (32) · 12-24 hours (long for an antihistamine) (1) · 4-12 hours (1) · 4-6 hours (3)

None (32) · 12-15 hours'"`UNIQ--ref-00000022-QINU`"' (1) · 3-6 hours (longer in hepatic impairment)'"`UNIQ--ref-00000378-QINU`"' (1) · 4-8 hours (longer in elderly, 9-13 hours)'"`UNIQ--ref-00000026-QINU`"' (1) · 5-6 hours'"`UNIQ--ref-00000EF9-QINU`"' (1) · ~6 hours'"`UNIQ--ref-00000018-QINU`"' (1)

None (32) · ~25% (oral)'"`UNIQ--ref-00000019-QINU`"' (1) · ~25% (oral, with extensive first-pass)'"`UNIQ--ref-00000023-QINU`"' (1) · ~40-60% (oral, with significant first-pass)'"`UNIQ--ref-00000027-QINU`"' (1) · ~60% (oral)'"`UNIQ--ref-00000379-QINU`"' (1) · ~80% (oral; reduced by significant first-pass)'"`UNIQ--ref-00000EFA-QINU`"' (1)

None (33) · Older agent with substantial use experience, including in hyperemesis gravidarum; broadly reassuring observational data'"`UNIQ--ref-00000024-QINU`"' (1) · Older agent with substantial use experience; broadly considered safe in pregnancy'"`UNIQ--ref-00000028-QINU`"' (1) · Older agent with substantial use experience; observational signals reassuring for first-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Widely used for hyperemesis gravidarum; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (33) · [[USLegal:Over-the-counter|OTC]] as Bonine and Dramamine Less Drowsy; [[USLegal:Prescription only|Rx-only]] as Antivert (1) · [[USLegal:Over-the-counter|OTC]] for most oral and topical formulations; [[USLegal:Prescription only|Rx-only]] for injectable (1) · [[USLegal:Prescription only|Rx-only]] in US (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for '''tardive dyskinesia''' (irreversible movement disorder), driving the 12-week chronic-use limit'"`UNIQ--ref-00000EFB-QINU`"' (1)